AZNCF (AstraZeneca) Short-Term Debt : $2,156 Mil (As of Dec. 2024)

View and export this data going back to 2009. Start your Free Trial

What is AstraZeneca Short-Term Debt?

AstraZeneca's Short-Term Debt for the quarter that ended in Dec. 2024 was $2,156 Mil.

AstraZeneca's quarterly Short-Term Debt declined from Jun. 2024 ($5,067 Mil) to Sep. 2024 ($1,253 Mil) but then increased from Sep. 2024 ($1,253 Mil) to Dec. 2024 ($2,156 Mil).

AstraZeneca's annual Short-Term Debt declined from Dec. 2022 ($5,225 Mil) to Dec. 2023 ($4,914 Mil) and declined from Dec. 2023 ($4,914 Mil) to Dec. 2024 ($2,156 Mil).

AstraZeneca Short-Term Debt Historical Data

The historical data trend for AstraZeneca's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AstraZeneca Short-Term Debt Chart

AstraZeneca Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Short-Term Debt

Get a 7-Day Free Trial

2,194.00

1,660.00

5,225.00

4,914.00

2,156.00

AstraZeneca Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Short-Term Debt	Get a 7-Day Free Trial															4,914.00	6,050.00	5,067.00	1,253.00	2,156.00

AstraZeneca Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

AstraZeneca Short-Term Debt Related Terms

Thank you for viewing the detailed overview of AstraZeneca's Short-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

AstraZeneca Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » AstraZeneca PLC (OTCPK:AZNCF) » Definitions » Short-Term Debt

Comparable Companies

Traded in Other Exchanges

AZN:USA AZN:Sweden AZN1:Mexico AZNN:Mexico AZNl:UK AZN:UK ZEGA:Germany ZEG:Germany ZEG:Germany ZEG:Germany ZEGA:Germany ZEG:Germany A1ZN34:Brazil AZN:Argentina

Address

1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, GBR, CB2 0AA

Website

https://www.astrazeneca.com

A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (about 40% of total revenue), cardiovascular, renal, and metabolic (25%), rare disease (17%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one third of its sales.